Medical Cannabis Pain Benefit, Risk and Effectiveness Perceptions Among Belarus Medical Students

  • Natallia Khamenka
  • Aliaksei Skuhareuski
  • Alexander Reznik
  • Richard IsralowitzEmail author
Brief Report


For centuries, the chemicals in cannabis and cannabinoids have been used for medical purposes. The psychoactive compound of cannabis, THC or tetrahydrocannabinols, is linked to a sense of euphoria or a “feel good” condition. A second compound is cannabidiol or CBD, not linked to causing a “high,” is thought to be responsible for many cannabis therapeutic effects (NIDA 2019).

Much advocacy is being generated in support of cannabis; and numerous countries have legalized the substance for medical purposes or are on the path of doing so (Krcevski-Skvarc et al. 2018). Epidemiological studies and randomized controlled trials evidence cannabis effective for treatment purposes, particularly chronic pain in adults – the most common reason people receive medical cannabis (USNAS 2017; Abrams 2018). However, details remain elusive about short- and long-term effects, benefits and risks linked to mental health, misuse and dependence, physical and cognitive impairment, and more (Di...



The authors thank Belarus State Medical University administrators and student participants for their cooperation with this study. This research was conducted with the generous support from Drs. Toby and Mort Mower to the Ben Gurion University of the Negev, Regional Alcohol and Drug Abuse Research (RADAR) Center.

Compliance with Ethical Standards:

Conflict of Interest

The authors declare that they do not have a conflict of interest.


  1. Abrams, D. I. (2018). The therapeutic effects of Cannabis and cannabinoids: an update from the national academies of sciences, engineering and medicine report. European Journal of Internal Medicine, 49, 7–11.CrossRefGoogle Scholar
  2. American Society for Clinical Oncology (ASCO) (2019). Oncologists see benefit of medical marijuana, but not comfortable prescribing. Retrieved from
  3. Baldwin, D. C., Hughes, P. H., Conard, S. E., Storr, C. L., & Sheehan, D. V. (1991). Substance use among senior medical students: a survey of 23 medical schools. Jama, 265(16), 2074–2078.CrossRefGoogle Scholar
  4. Legalize Belarus (2019). What is legalize Belarus? Retrieved from
  5. Chan, M. H., Knoepke, C. E., Cole, M. L., McKinnon, J., & Matlock, D. D. (2017). Colorado medical students’ attitudes and beliefs about marijuana. Journal of General Internal Medicine, 32(4), 458–463.CrossRefGoogle Scholar
  6. Di Forti, M., Quattrone, D., Freeman, T. P., Tripoli, G., Gayer-Anderson, C., Quigley, H., & La Barbera, D. (2019). The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. The Lancet Psychiatry, 6(5), 427–436.CrossRefGoogle Scholar
  7. Doblin, R., & Kleiman, M. A. (1991). Medical use of marijuana. Annals of Internal Medicine, 114(9), 809–810.CrossRefGoogle Scholar
  8. Dorman, M. (2018). Belarus Digest: Cannabis Reform in Belarus? Media appearances. Retrieved from
  9. Gage, S. H. (2019). Cannabis and psychosis: triangulating the evidence. The Lancet Psychiatry, 6(5), 364–365.CrossRefGoogle Scholar
  10. Global Commission on Drug Policy (2018). Commissioners Clark and Kazatchkine: “Time for a change in drug policy in Belarus”. Retrieved from
  11. Isralowitz, R., & Reznik, A. (2018). Cannabis use in Israel: a cross sectional overview of multiple study groups. International Journal of Mental Health and Addiction, 16(4), 832–842.CrossRefGoogle Scholar
  12. Kollas, C. (2012). Medical: What Should be Palliative. Retrieved from
  13. Kilmer, J. R., Hunt, S. B., Lee, C. M., & Neighbors, C. (2007). Marijuana use, risk perception, and consequences: Is perceived risk congruent with reality? Addictive Behaviors, 32(12), 3026–3033.CrossRefGoogle Scholar
  14. Kondrad, E., & Reid, A. (2013). Colorado family physicians' attitudes toward medical marijuana. The Journal of the American Board of Family Medicine, 26(1), 52–60.CrossRefGoogle Scholar
  15. Krcevski-Skvarc, N., Wells, C., & Häuser, W. (2018). Availability and approval of cannabis-based medicines for chronic pain management and palliative/supportive care in Europe: a survey of the status in the chapters of the European Pain Federation. European Journal of Pain, 22(3), 440–454.CrossRefGoogle Scholar
  16. Mirelman, D., Waissengrin, B., Goldway, N., Sharon, H., Brill, S., & Wolf, I. (2019). Use of medical cannabis: perceptions of Israeli oncologists. The Lancet Oncology, 20(4), 475–477.CrossRefGoogle Scholar
  17. National Institute on Drug Abuse (NIDA) (2019). Marijuana as medicine. Retrieved from
  18. Ritchie, H., & Roser, M. (2018). Alcohol consumption. Our World in Data. Retrieved from
  19. Taylor, T. (2008). Supporting research into the therapeutic role of marijuana: a position paper of the American College of Physicians. Retrieved from
  20. The National Academies of Sciences (USNAS) (2017). The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Retrieved from
  21. World Health Organization (WHO) (2018a). European Centre for Disease Prevention and WHO Regional Office for Europe. HIV/AIDS surveillance in Europe – 2017 data. Retrieved from
  22. World Health Organization (WHO) (2018b). News Briefing – 40th WHO Expert Committee on Drug Dependence (ECDD). Retrieved from

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Psychiatry & Medical PsychologyBelarusian State Medical UniversityMinskBelarus
  2. 2.Faculty of General MedicineBelarusian State Medical UniversityMinskBelarus
  3. 3.Regional Alcohol and Drug Abuse Research CenterBen Gurion University of the NegevBeer ShevaIsrael

Personalised recommendations